”We’re thrilled to work with Mayo Clinic as we enter the US market, targeting health conscious and pre-diabetic individuals." Lihi Segal, CEO, DayTwo
(PRWEB) December 14, 2016
DayTwo (http://www.daytwo.com), the leader in actionable health solutions based on gut microbiome, is pleased to announce its ongoing collaboration with the Mayo Clinic to bring the DayTwo™ Personalized Nutrition Solution to early adopters in the US.
DayTwo provides actionable health solutions based on gut microbiome aimed at improving health and preventing disease, utilizing the DayTwo™ Microbiome Platform. Its first product, the DayTwo Personalized Nutrition Solution, is based on groundbreaking research from the Weizmann Institute of Science in Israel, led by Prof. Eran Segal and Dr. Eran Elinav (Cell, Nov15). The research showed there was no “one size fits all” approach to nutrition, and different people responded differently to the same food. Hence, nutrition guidelines aimed at balancing blood sugar levels must be personally tailored. As high blood sugar is linked to energy dips, excessive hunger, weight gain, and increased risk for diseases like obesity, diabetes, and hypertension, balancing blood sugar levels presents a significant health benefit.
The research generated an algorithm for predicting individualized blood glucose response to different foods based on gut microbiome information and other personal parameters. This algorithm was further developed by DayTwo and the Weizmann Institute, and predicts blood sugar response to thousands of different foods and meals.
The collaboration is managed by Heidi Nelson, M.D., the Director of the Microbiome Program at the Mayo Clinic Center of Individualized Medicine
According to Lihi Segal, DayTwo CEO, this collaboration with Mayo Clinic is perfectly aligned with its launch in the U.S. ”We’re thrilled to work with Mayo Clinic as we enter the US market, targeting health conscious and pre-diabetic individuals” said Ms. Segal. “Providing our solution to US consumers in a clinical trial setting with Mayo Clinic allows us to calibrate our predictive algorithm for the US Market.”
Mayo Clinic has a financial interest in DayTwo and will participate in DayTwo’s Series A funding round.
DayTwo (http://www.daytwo.com) is the world's first provider of health improvement and disease prevention solutions based on Gut Microbiome research. Its first product, based on groundbreaking research led by Prof. Eran Segal and Dr. Eran Elinav from the Weizmann Institute of Science in Israel, and exclusively licensed to DayTwo, is a personalized nutrition platform. It aims to normalize blood sugar levels and reduce risk for metabolic diseases like obesity, diabetes, and hypertension, leveraging the world's largest and most detailed microbiome database. DayTwo's product pipeline includes additional microbiome-based diagnostic and therapeutic solutions.
Lihi Segal, CEO
Phone number: +972 9-7498003
About Mayo Clinic
Additional information regarding the Mayo Clinic and the Center For Individualized Medicine can be found here: (http://mayoresearch.mayo.edu/center-for-individualized-medicine/).